Author: Li, Xiao-Bo; Wang, Shu-Qing; Xu, Wei-Ren; Wang, Run-Ling; Chou, Kuo-Chen
Title: Novel Inhibitor Design for Hemagglutinin against H1N1 Influenza Virus by Core Hopping Method Document date: 2011_11_30
ID: 16syz1o7_4
Snippet: Owing to its deep active site cleft, the NA has been an attractive target for drug design. Both zanamivir and oseltamivir were designed by modifying the sialic acid (SA) structure. The two FDA-approved clinical drugs were once successfully used to inhibit the spread of influenza viral progeny [15] by binding to viral surface glycoprotein of neuraminidase (NA) [15] . However, it has also been found from several clinical cases [16, 17, 18] that ose.....
Document: Owing to its deep active site cleft, the NA has been an attractive target for drug design. Both zanamivir and oseltamivir were designed by modifying the sialic acid (SA) structure. The two FDA-approved clinical drugs were once successfully used to inhibit the spread of influenza viral progeny [15] by binding to viral surface glycoprotein of neuraminidase (NA) [15] . However, it has also been found from several clinical cases [16, 17, 18] that oseltamivir failed to treat avian influenza virus. It is both antigenic drift (sequence base mutations) and antigenic shift (genetic recombination) of segmented RNA genome of influenza viruses that have caused the NA inhibitor being resistant [19, 20] .
Search related documents:
Co phrase search for related documents- antigenic drift and avian influenza virus: 1, 2, 3, 4, 5, 6, 7
- antigenic drift and clinical case: 1
- antigenic drift and clinical drug: 1
- antigenic drift and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antigenic shift and avian influenza virus: 1, 2, 3, 4
- antigenic shift and genetic recombination: 1
- antigenic shift and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- attractive target and avian influenza virus: 1
- attractive target and base mutation: 1
- attractive target and clinical drug: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- attractive target and drug design: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- attractive target and drug design attractive target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- attractive target and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- avian influenza virus and clinical case: 1, 2, 3, 4, 5, 6
- avian influenza virus and clinical drug: 1, 2
- avian influenza virus and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- avian influenza virus and NA inhibitor: 1
- base mutation and influenza virus: 1, 2, 3, 4
- clinical case and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date